Specify a stock or a cryptocurrency in the search bar to get a summary
Apogee Therapeutics, Inc. Common Stock
APGEApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts. Address: 221 Crescent Street, Waltham, MA, United States, 02453
Analytics
WallStreet Target Price
88.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures APGE
Dividend Analytics APGE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History APGE
Stock Valuation APGE
Financials APGE
Results | 2019 | Dynamics |